Back to Results

Provectus Biopharmaceuticals Inc (PVCT)

Provectus Biopharmaceuticals Inc. is a clinical-stage biotechnology company listed on OTC Markets under the ticker PVCT. Based in Knoxville, Tennessee, the company focuses on developing immunotherapy medicines for a range of diseases. Its lead compound is rose bengal sodium, a halogenated xanthene, and its pipeline includes PV-10 for stage III and IV melanoma, certain liver cancers, blood cancers, and relapsed or refractory pediatric solid tumors. The company is also developing PH-10 for psoriasis, atopic dermatitis, and skin inflammation, as well as PV-305 for infectious keratitis. Additional programs cover oral and intranasal formulations for infectious and inflammatory conditions, wound healing, tissue regrowth, and selected bacterial and fungal infections. Provectus Biopharmaceuticals was founded in 2002 and adopted its current name in December 2013.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-PVCT
$0.056
8.7% Upside
Fair
Not available
Not available
Weak
0.0%
November 13, 2026
21.77 M
25.888 M
13.0%
92.3%
-264.6
51.1%
Valuation • Fair Value

Provectus Biopharmaceuticals Inc (OTC-PVCT) Fair Value by Valuation Model

Review the available estimates for Provectus Biopharmaceuticals Inc (OTC-PVCT), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.056

Estimated upside of 8.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.059

Discounted cash flow valuation reference.

Comps Fair Value

$0.051

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for Provectus Biopharmaceuticals Inc (OTC-PVCT) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Provectus Biopharmaceuticals Inc (OTC-PVCT)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

0 K

Current operating scale indicator.

Revenue Forecast

336.108 K

Forward revenue estimate.

EBITDA

-4.153 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Provectus Biopharmaceuticals Inc (OTC-PVCT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Provectus Biopharmaceuticals Inc (OTC-PVCT)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

5

Mid-range quality score.

Altman Z-Score

-264.6

Lower score that deserves closer risk review.

FCF / Net Income

51.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Provectus Biopharmaceuticals Inc (OTC-PVCT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Provectus Biopharmaceuticals Inc (OTC-PVCT)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

52

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Provectus Biopharmaceuticals Inc (OTC-PVCT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Provectus Biopharmaceuticals Inc (OTC-PVCT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Provectus Biopharmaceuticals Inc (OTC-PVCT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Provectus Biopharmaceuticals Inc (OTC-PVCT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Provectus Biopharmaceuticals Inc (OTC-PVCT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Provectus Biopharmaceuticals Inc (OTC-PVCT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Provectus Biopharmaceuticals Inc (OTC-PVCT) Stock FAQ

Data-supported answers about Provectus Biopharmaceuticals Inc (OTC-PVCT), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.056
Estimated upside 8.7%
Valuation Rating
Undervalued
Estimated upside of 8.7%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Provectus Biopharmaceuticals Inc (OTC-PVCT) is $0.056. This implies an estimated upside of 8.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 8.7% versus the current market price.

The current financial health read for Provectus Biopharmaceuticals Inc (OTC-PVCT) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Provectus Biopharmaceuticals Inc (OTC-PVCT) is November 13, 2026.

The latest available data indicates no current dividend yield for Provectus Biopharmaceuticals Inc (OTC-PVCT).

The current market capitalization listed for Provectus Biopharmaceuticals Inc is 21.77 M.

The current enterprise value listed for Provectus Biopharmaceuticals Inc is 25.888 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Provectus Biopharmaceuticals Inc is OTC-PVCT, and the stock is listed on OTC Markets.

Provectus Biopharmaceuticals Inc (OTC-PVCT) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Provectus Biopharmaceuticals Inc is 13.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Provectus Biopharmaceuticals Inc is 92.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B